MM&M

AstraZeneca’s Fasenra ad encourages asthma patients to reclaim their lives

Asthma season is in full swing and AstraZeneca is raising awareness about its severe asthma treatment, Fasenra, as part of its ongoing Stepping Back Out campaign. The latest installment of the ...
Nasdaq

AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids

AstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab), for use in children. The regulatory body has now approved Fasenra as an add-on maintenance ...
zacks

CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease

AstraZeneca (AZN Quick Quote AZN - Free Report) announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the regulatory filing seeking label expansion in ...
zacks

AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease

AstraZeneca (AZN Quick Quote AZN - Free Report) announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab) for a new indication. The regulatory body has now approved Fasenra ...
FiercePharma

AstraZeneca's Fasenra woes continue as it comes up short in eosinophilic esophagitis

In March, AstraZeneca failed to get Fasenra over the FDA finish line to treat rhinosinusitis. Now, the company has reported mixed results in a phase 3 trial in eosinophilic esophagitis. (AstraZeneca) ...
MM&M

Targeting eosinophilic asthma, AstraZeneca wants HCPs to Move Forward with Fasenra

AstraZeneca experienced some setbacks last year on its quest to expand its asthma drug Fasenra to treat other conditions like rhinosinusitis and eosinophilic esophagitis. However, the British pharma ...
Medical Xpress

FDA adds Fasenra indication for severe asthma in children

The U.S. Food and Drug Administration has approved an additional indication for AstraZeneca's Fasenra (benralizumab) as an add-on maintenance treatment for patients aged 6 to 11 years with severe ...
Business Wire

FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated ...
FiercePharma

Regeneron, AZ eye green lights after separate trial wins for Dupixent, Fasenra in inflammatory conditions

Regeneron and Sanofi's Dupixent led to significant reductions in sinus opacification, nasal congestion and nasal polyps versus placebo in patients with allergic fungal rhinosinusitis. At the American ...